

Amendments to the Claims

Please cancel Claims 1, 2, 4-15, 18, 19, and 21-32. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

Claims 1-15 (Canceled)

16. (Withdrawn) An immunoassay method for detecting human TNF in a sample, comprising:
 - (a) contacting said sample with an antibody according to claim 36, or a TNF binding fragment thereof, in detectably labeled form; and
 - (b) detecting the binding of the antibody to said TNF.
17. (Original) The chimeric antibody cA2.

Claims 18-32 (Canceled)

33. (Withdrawn) An immunoassay method for detecting human TNF in a sample, comprising:
 - (a) contacting said sample with an antibody according to claim 38, or a TNF binding fragment thereof, in detectably labeled form; and
 - (b) detecting the binding of the antibody to said TNF.
34. (Canceled)
35. (Canceled)
36. (Canceled)
37. (Original) A chimeric antibody comprising at least part of a human IgG1 constant region and at least part of a non-human immunoglobulin variable region, said antibody capable

of binding an epitope specific for human TNF α , wherein the non-human immunoglobulin variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO: 5.

38. (Canceled)
39. (Canceled)
40. (Original) A polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO: 5 or at least one binding fragment thereof, wherein said polypeptide binds to hTNF α .
41. (Original) A polypeptide of Claim 40, wherein said polypeptide neutralizes hTNF α .
42. (Original) A polypeptide of Claim 40, wherein said polypeptide inhibits hTNF α .
43. (Canceled)
44. (Canceled)
45. (Original) A polypeptide of Claim 40 which competitively inhibits the binding of monoclonal antibody cA2 to hTNF α .
46. (Canceled)
47. (Canceled)
48. (Original) A polypeptide comprising at least one binding fragment of SEQ ID NO: 3, wherein said polypeptide binds to hTNF α and competitively inhibits the binding of monoclonal antibody cA2 to hTNF α .

49. (Original) A polypeptide comprising at least one binding fragment of SEQ ID NO: 5, wherein said polypeptide binds to hTNF α and competitively inhibits the binding of monoclonal antibody cA2 to hTNF α .
50. (Original) A polypeptide of Claim 45 having a hTNF α binding affinity, measured as an affinity constant (K_a), of at least 1×10^8 liters/mole.
51. (Original) A polypeptide of Claim 45 having a hTNF α binding affinity, measured as an affinity constant (K_a), of at least 1×10^9 liters/mole.
52. (Original) A polypeptide of Claim 45 which neutralizes hTNF α with an ID₅₀ of at least about 1 μ g/ml.
53. (Original) A polypeptide of Claim 45 which neutralizes hTNF α with an ID₅₀ of at least about 100 ng/ml.
54. (Original) A polypeptide of Claim 45 which neutralizes hTNF α with an ID₅₀ of at least about 15 ng/ml.
55. (Original) A fusion protein comprising SEQ ID NO: 3 or SEQ ID NO: 5 or a binding fragment thereof, wherein said fusion protein binds to hTNF α .